{"id":"W2129184374","doi":"10.1086/444457","title":"Clinic-Initiated, Twice-Daily Oral Famciclovir for Treatment of Recurrent Genital Herpes: A Randomized, Double-Blind, Controlled Trial","year":2005,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Research Manitoba; Health Sciences Centre; University of British Columbia","funders":"Gilead Sciences; Sanofi; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Famciclovir; Penciclovir; Medicine; Valaciclovir; Placebo; Randomized controlled trial; Dose; Dermatology; Herpes Genitalis; Aciclovir; Genital herpes; Internal medicine; Viral disease; Herpesviridae; Herpes simplex virus; Virology; Virus; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002477211,0.001343404,0.003811775,0.0006012343,0.0006079412,0.001197554,0.001350417,0.003876899,0.008283079],"category_scores_gemma":[0.003219441,0.0007473938,0.002037738,0.0006007691,0.001093119,0.0009781007,0.0003098427,0.002563206,0.001070939],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006718267,"about_ca_system_score_gemma":0.001507378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001023174,"about_ca_topic_score_gemma":0.002006515,"domain_scores_codex":[0.9984971,0.0008486366,0.0001111071,0.0002852984,0.0001252168,0.0001326968],"domain_scores_gemma":[0.998422,0.0005989945,0.0003828532,0.00010505,0.0001434763,0.0003476836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9826132,0.004195502,0.0003060534,0.001384225,0.0008051362,0.00003707959,0.00003026948,0.0001017977,0.001034694,0.00006746016,0.0005153097,0.008909454],"study_design_scores_gemma":[0.9901807,0.009094509,0.00027474,0.0000274164,0.0001430346,0.000009285173,0.000003900633,0.00007244551,0.00005077809,0.00001647354,0.000123035,0.000003658171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9447653,0.02707169,0.001585403,0.001451573,0.00220863,0.01651952,0.002438663,0.0003554135,0.003603724],"genre_scores_gemma":[0.9582573,0.01072959,0.00393436,0.002445976,0.001713722,0.01791047,0.001585389,0.00004156534,0.003381681],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008283079,"threshold_uncertainty_score":0.02770966,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1329511317894969,"score_gpt":0.4445807655639828,"score_spread":0.3116296337744859,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}